Warner-Lambert/Glaxo
This article was originally published in The Tan Sheet
Executive Summary
Finalize joint venture to develop, seek approval and market over-the-counter versions of Glaxo prescription drugs, initially focusing on an Rx-to-OTC switch of Zantac (ranitidine). Warner- Lambert and Glaxo announced a letter of intent agreement to form the joint venture in July ("The Tan Sheet" Aug. 2, p. 4). The entity will be managed by a soon-to-be-announced committee of representatives from each company, with day-to-day operations being handled by Warner-Lambert. Warner-Welcome, a separate joint venture formed with Burroughs Wellcome, will market OTC products arising from the GIaxo/W-L deal.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning